ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. The company was founded in 2008 and is based in Yonkers, New York.
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Exebacase Expanded Access Program Initiated On October 26, 2020, ContraFect Corp. (CFRX) announced the initiation of an expanded access program for exebacase to make it available to COVID-19 patients that are suffering from persistent bacteremia caused by Staphylococcus aureus . Exebacase will be available to use
YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients. Exebacase has been granted Breakthrough Therapy designation for the treatment of MRSA bloodstream infections by the U.S. Food and Drug Administration (FDA). The Company is providing expanded access to exebacase under a treatment protocol available to ...
NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Earnings and Valuation This table compares NextCure and ContraFect’s top-line revenue, earnings per share and valuation. Gross […]